NextCure Prepares for SITC Annual Meeting Presentations
NextCure's Upcoming Presentations at Major Cancer Meeting
NextCure, Inc. (NASDAQ: NXTC), a pioneering biopharmaceutical company focused on developing innovative therapies for cancer treatment, is geared up for the Society for Immunotherapy of Cancer (SITC) annual meeting. This event is set to take place in Houston, bringing together experts and professionals in cancer immunotherapy from November 6-10, 2024.
Insights on New Research Findings
At this significant convention, NextCure aims to present exciting pre-clinical data surrounding their novel therapies, specifically LNCB74 and biomarker findings related to the NC410 combination study. These presentations will illuminate their groundbreaking work in targeting B7-H4 expressing cancers and enhancing anti-tumor responses, especially in advanced colorectal cancer.
Poster Presentation Details
NextCure's presentations will include:
Title: LNCB74 is a B7-H4 antibody-drug conjugate with a ?-glucuronide linker-MMAE payload system to enhance therapeutic index in B7-H4 expressing cancers.
Lead Author: Shannon M. Kahan.
Abstract Number: 1051.
Session Date & Time: November 8, 2024, from 5:30 to 7:00 PM.
Title: NC410 in combination with pembrolizumab to improve anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI-naïve MSS/MSI-L colorectal cancer (CRC).
Lead Author: Alina Barbu.
Abstract Number: 632.
Session Date & Time: November 9, 2024, from 7:10 to 8:30 PM.
Company Overview and Mission
NextCure is devoted to transforming cancer care through advanced therapies that target patients who have not achieved satisfactory results from current treatments. Their focus lies in developing therapies based on innovative mechanisms of action, including antibody-drug conjugates and a range of protein-based treatments. The team is committed to understanding critical biological pathways and how these influence interactions within the tumor microenvironment and the subsequent immune responses.
Innovative Therapies in Development
The company is making strides in developing novel therapeutics for various cancer types, highlighting their distinct approach towards treating those with limited options. By leveraging advanced research and building a comprehensive understanding of cancer biology, NextCure continuously seeks to improve therapeutic outcomes for patients whose conditions may be resistant to traditional therapies.
Contacting NextCure for Inquiries
For those interested in learning more about NextCure's innovative approaches and ongoing research efforts, investor inquiries can be directed to:
Timothy Mayer, Ph.D.
Chief Operating Officer
NextCure, Inc.
(240) 762-6486
Email: IR@nextcure.com
Frequently Asked Questions
What will be presented at the SITC Annual Meeting?
NextCure will present pre-clinical data on their therapies, LNCB74 and NC410, at the SITC Annual Meeting.
When is the SITC Annual Meeting scheduled?
The meeting will occur from November 6-10, 2024, in Houston.
Who are the lead authors for the presentations?
The lead authors for the posters are Shannon M. Kahan and Alina Barbu.
What is the focus of NextCure's research?
NextCure focuses on developing therapies for cancer patients who do not respond to current treatments.
How can I reach NextCure for more information?
Inquiries can be made by contacting Timothy Mayer, COO, at (240) 762-6486 or via email at IR@nextcure.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.